Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 2/20 | 0.58 |
| ▸ | IL23R | Q5VWK5 | 10/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.55 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.55 |
| ▸ | GHSR | Q92847 | 2/20 | 0.55 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29419491 | 1.00 | NPBWR1 (0.58) | NPBWR1IL23ROPRM1OPRD1GHSR | |
| SCHEMBL29511074 | 0.95 | GHSR (0.59) | GHSR | |
| SCHEMBL30029017 | 0.95 | GHSR (0.59) | GHSR | |
| SCHEMBL29480592 | 0.94 | OPRD1 (0.57) | NPBWR1IL23ROPRM1OPRD1PRMT1 | |
| SCHEMBL31661149 | 0.94 | GHSR (0.61) | GHSR | |
| SCHEMBL30518104 | 0.94 | IL23R (0.63) | NPBWR1IL23R | |
| SCHEMBL29511199 | 0.94 | NPBWR1 (0.57) | NPBWR1IL23RGHSR | |
| SCHEMBL30866237 | 0.94 | NPBWR1 (0.55) | NPBWR1IL23ROPRM1OPRD1GHSR | |
| SCHEMBL30599227 | 0.93 | NPBWR1 (0.58) | NPBWR1IL23RGHSRPRMT1 | |
| SCHEMBL30919239 | 0.93 | GHSR (0.61) | NPBWR1GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12508329-B2 | Radiotherapeutic and companion imaging agents to target MC1R | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20230211022-A1 | RADIOTHERAPEUTIC AND COMPANION IMAGING AGENTS TO TARGET MC1R | WAKE FOREST UNIVERSITY | 2023-07-06 | — | — | US | disclosed |
| US-11406723-B2 | Radiotherapeutic and companion imaging agents to target MC1R | WAKE FOREST UNIVERSITY | 2022-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230211022-A1 | RADIOTHERAPEUTIC AND COMPANION IMAGING AGENTS TO TARGET MC1R | MC1R, MC3R, MC5R | NPBWR1 498/4885IL23R 945/4885OPRM1 668/4885 |
| US-12508329-B2 | Radiotherapeutic and companion imaging agents to target MC1R | MC1R, MC3R, MC5R | NPBWR1 1114/4885IL23R 68/4885OPRM1 437/4885 |
| US-11406723-B2 | Radiotherapeutic and companion imaging agents to target MC1R | MC1R, MC3R, MC5R | NPBWR1 417/4885IL23R 848/4885OPRM1 461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.